MGL-3196 (resmetirom)
MGL-3196-06
Phase 2 small_molecule completed
Quick answer
MGL-3196 (resmetirom) for Heterozygous Familial Hypercholesterolemia is a Phase 2 program (small_molecule) at Madrigal Pharmaceuticals EU Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Madrigal Pharmaceuticals EU Limited
- Indication
- Heterozygous Familial Hypercholesterolemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed